Management of the contralateral breast in patients with hereditary breast cancer

Breast

Volumn 9, Issue 6, 2000, Pages 301-305

  Eccles, D M ^a   Gareth Evans, D ^b  

^a PRINCESS ANNE HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; PROTEIN P53; TAMOXIFEN;

BREAST CANCER; BREAST CARCINOGENESIS; BREAST RECONSTRUCTION; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; ONSET AGE; OVARIECTOMY; PENETRANCE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

EID: 0033665052     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2000.0143     Document Type: Review

References (52)

1. Autosomal dominant inheritance of early onset breast cancer
2. GeneticEpidemiology of early onset breast cancer
3. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence
4. BRCA1 mutations in Southern England
5. BRCA1 mutations in a population-based sample of young women with breast cancer
6. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals
7. Breast cancer genes - What are the real risks?
8. Linkage of early-onset familial breast cancer to chromosome 17q21
9. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1
10. Localisation of a breast cancer susceptibility gene BRCA2 to chromosome 13q12-13
11. Identification of the breast cancer susceptibility gene BRCA2
12. Awakening angels
13. Li Fraumeni syndrome a molecular and clinical review
14. Radiation induced G(1) arrest is not defective in fibroblasts from Li-Fraumeni families without TP53 mutations
15. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutations
16. A serine/ threonine kinase gene defective in Peutz-Jeghers syndrome
17. Breast and ovarian cancer incidence in BRCA1 carriers
18. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 amongst Ashkenazi Jews
19. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer
20. Reanalysis and results after 12 years of follow-up in a randomised clinical trial comparing total mastectomy with lumpectomy with and without irradiation in the treatment of breast cancer
21. 10-year results of a comparison of conservation with mastectomy in the treatment of stage I and stage II breast cancer
22. Breast conservation is the treatment of choice in small breast cancer - Long term results of a randomised trial
23. Polychemotherapy for early breast cancer: An overview of the randomised trials
24. Tamoxifen for early breast cancer: An overview of the randomized trials
25. Ovarian ablation in early breast cancer: Overview of the randomised trials
26. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer
27. The histologic phenotypes of breast carcinoma occuring before age 40 years in women with and without BRCA1 and BRCA2 germline mutations
28. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
29. Survival and tumour characteristics of breast-cancer patients with germ-line mutations of BRCA1
30. Ductal carcinoma in situ (DCIS) may be a feature of hereditary breast cancer (HBC)
31. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer
32. Breast cancer incidence, penetrance and survival in probable carrieres of BRCA1 gene mutations in families linked to BRCA1 on chromosome 17q12-21
33. Pathobiology, prognosis and BRCA1 and BRCA2 gene linkage
34. Analysis of a panel of patients with childhood adrenocortical tumours for germline TP53 mutations
35. Family history and treatment outcomes in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer
36. Management of hereditary breast cancer
37. Is breast conservation appropriate for women with a family history of breast cancer?
38. Breast screening in women aged 40-49 years: What next?
39. Breast-cancer screening with mamography in women aged 40-49 years
40. Screening women aged less than 50 years with a family history of breast cancer
41. Screening by mammography, women with a family history of breast cancer
42. Prospective findings in breast cancer kindreds: Annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer
43. Ten-year risk of false positive screening mammograms and clinical breast examinations
44. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
45. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
46. Status of antiestrogen breast cancer prevention trials
47. Is tamoxifen effective in prevention of breast cancer
48. Tamoxifen in treatment of intraductal breast cancer: National surgical adjuvant breast and bowel project B-24 randomised controlled trial
49. Cultural basis for differences between US and clinical recommendations for women at increased risk of breast and ovarian cancer
50. Attitudes towards preventive options for hereditary breast/ovarian cancer: Cultural differences between Marseille, Manchester and Montreal
51. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
52. Utilisation of prophylactic mastectomy in 10 European centres